News on research and diagnostic development for pathogenic diseases.
The company, which also said it is short on funds, may have to pay $18.3 million to Hudson Bay Master Fund if forebearance is not granted for the default.
Developers can use the Zika virus samples to ascertain whether their tests can help distinguish Zika infection from similar diseases.
Researchers used mass spectrometry to identify unique biochemical markers that differentiate Lyme disease from southern tick-associated rash Illness.
The company also announced a deal to provide in-house testing services to drugmaker Biotest, as well as changes to its management team.
BioMérieux is deploying consultants to advise hospitals about the most optimal testing options and how to implement them.
